MXD3 and invasive breast carcinoma: Further, metastatic pheochromocytoma and paraganglioma (PCPG), head and neck squamous cell carcinoma (HNSC), thyroid carcinoma (THCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) tumors, exhibited higher expression levels of MXD3 than the corresponding primary tumors (Fig. 3C).